Kiniksa Pharmaceuticals, Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sanj K. Patel
- Full Time Employees
- 315
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Clarendon House Hamilton United States of America HM 11
- IPO Date
- May 25, 2018
- CIK
- 0001730430
- Website
- kiniksa.com
- Similar Companies
- Business
- Kiniksa Pharmaceuticals International, plc (KNSA) is a commercial-stage biopharmaceutical company that discovers, acquires, develops and commercializes therapeutic medicines for patients with debilitating diseases featuring significant unmet medical needs, with a primary focus on cardiovascular and inflammatory indications worldwide. The company markets ARCALYST (rilonacept), an interleukin-1 alpha and beta inhibitor approved for treating recurrent pericarditis, an inflammatory cardiovascular disease; its pipeline includes vixarelimab, a monoclonal antibody in Phase 2b trials for chronic inducible urticaria and other pruritic skin diseases; KPL-387, a preclinical Fc-modified immunoglobulin G2 monoclonal antibody that received FDA Orphan Drug Designation for pericarditis; and other early-stage candidates targeting unmet needs in immunology and beyond. Founded in 2015 and headquartered in London, United Kingdom, with primary U.S. operations in Lexington, Massachusetts, the company maintains additional facilities in Zug, Switzerland, and La Jolla, California, supporting global development and commercialization efforts. In June 2024, Kiniksa Pharmaceuticals, Ltd. changed its name to Kiniksa Pharmaceuticals International, plc to reflect its expanded international presence; recent highlights include robust ARCALYST net product revenue growth of 61% year-over-year to $180.9 million in Q3 2025, raised full-year 2025 sales guidance to $560-$580 million, a return to profitability with $18.4 million net income in Q3 2025, and pipeline advancement via FDA Orphan Drug Designation for KPL-387 in pericarditis.
A Look at Kiniksa Pharmaceuticals International PLC (KNSA) After 4.8% Decline -- GF Value $46.92 vs Price $48.41
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa: Increased Outlook For Arcalyst, Augmented By Pipeline Maturation
Breakfast News: Enphase Dips As Solar Demand Dims
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge
Ross Moat Sells 1,703 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High – Still a Buy?
Aberdeen Group plc Buys 241,876 Shares of Kiniksa Pharmaceuticals International, plc $KNSA
AI-Fueled Trio Leads 5 Stocks To Watch Near Buy Points
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts
Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference